Blockade of the mitogen-activated protein (MAP) kinase pathway suppresses growth of colon cancer in vivo. Here we demonstrate a direct link between the extracellular signal-regulated kinase ERK2 and the growth-promoting cell adhesion molecule, integrin avb6, in colon cancer cells. Down-regulation of b6 integrin subunit expression inhibits tumour growth in vivo and MAP kinase activity in response to serum stimulation. In avb6-expressing cells ERK2 is bound only to the b6 subunit. The increase in cytosolic MAP kinase activity upon epidermal growth factor stimulation is all accounted for by b6-bound ERK. Deletion of the ERK2 binding site on the b6 cytoplasmic domain inhibits tumour growth and leads to an association between ERK and the b5 subunit. The physical interaction between integrin avb6 and ERK2 de®nes a novel paradigm of integrin-mediated signalling and provides a therapeutic target for cancer treatment.
Introduction
Amongst the dierent intracellular kinase families, mitogen activated protein (MAP) kinases behave as a convergence point for diverse receptor-initiated growth-signalling events initiated at the plasma membrane. In turn, MAP kinases drive cell cycle progression through modulation of cyclin D1 expression and associated cyclin-dependent kinase activity (Lavoie et al., 1996) . Extracellular signal-regulated kinases (ERKs) comprise a sub-family of MAPs that are activated by phosphorylation of tyrosine and threonine residues by MAP kinase kinases (MEKs) (Payne et al., 1991) . This signalling cascade begins at the plasma membrane via non-receptor tyrosine kinases and growth factors acting through membrane-associated receptor tyrosine kinases (Boulton et al., 1991; Schlaepfer and Hunter, 1997; Giancotti and Ruoslahti, 1999) . The importance of the MAP kinase pathway in promoting cancer growth in vivo is now no longer in question. For example, MAP kinases have been shown to be important in experimental tumour metastases (Mansour et al., 1994) and MAP kinases have been shown to be highly activated during the late progression of colorectal cancer (Licato et al., 1997) . In a large study of primary tumours of diverse origins, high frequencies of MAP kinase activation have been observed (Hoshino et al., 1999) , although the precise cause of the constitutive activation of the MAP kinase signalling pathway remains unclear. In a recent breakthrough in this ®eld, a highly potent inhibitor of MAP kinase activation has been identi®ed which is capable of inhibiting human cancer growth in immune-de®cient mice (Sebolt-Leopold et al., 1999) .
Integrins comprise a family of cell surface adhesion receptors that also activate the MAP kinase cascade leading to transcription of growth-promoting genes (Hynes, 1992; Clark and Brugge, 1995; Giancotti and Ruoslahti, 1999) . Each integrin consists of an alpha (a) and beta (b) subunit molecule in close association which form a structural and functional bridge between the extracellular matrix scaolding outside cells and cytoskeletal proteins within a cell (Hynes, 1992) . The cytoplasmic tails of integrins are generally short and transduce signals by associating with adaptor proteins that connect the integrin, cytoskeleton, cytoplasmic kinases and transmembrane growth factor receptors (Giancotti and Ruoslahti, 1999) . Activation of ERKs in response to integrin ligation is thought to be especially important when the concentration of growth factors available to a cell is limited (Giancotti and Ruoslahti, 1999) . In addition, integrin ligation with extracellular matrix substrates has recently been shown to be a pre-requisite for translocation of activated ERK not only to the nucleus but also to plasma membrane focal adhesion sites (Aplin et al., 2001; Fincham et al., 2000) .
Within the av integrin subfamily, the avb6 integrin is not expressed in normal epithelial cells; however, it becomes highly expressed during tumorigenesis and the b6 integrin subunit is thought to be widespread in cancers of various origins including lung, breast, pancreas, ovary, skin as well as in the tracheal airway epithelium of heavy smokers (Sheppard et al., 1990; Breuss et al., 1995) . For example, induction of avb6 expression in oral leukoplakia appears to be a necessary pre-requisite for progression to squamous cell cancers (Hamidi et al., 2000) and de novo expression of avb6 in oral squamous and colon cancers is seen particularly at the advancing tumour edge (Thomas et al., 1997; Agrez et al., 1996) . In breast cancer, avb6 expression has recently been linked to more advanced tumours (Arihiro et al., 2000) and we have previously reported that heterologous expression of avb6 in colon cancer promotes tumour cell proliferation . In the present study, we sought to identify the signalling pathway by which the b6 integrin subunit enhances colon cancer growth.
Results
Antisense b6 suppresses tumour growth in vivo and MAP kinase activity WiDr and HT29 cells, which constitutively express avb6 (Niu et al., 2001) , were stably transfected with b6 in the antisense orientation resulting in markedly reduced b6 subunit expression as shown for HT29 parent transfectants and three WiDr clones at the transcript and protein levels (Figure 1a ± d) . Control transfectants contained vector alone (mock). The av subunit binds multiple b integrin subunits besides b6, none of which was down-regulated as a consequence of antisense transfection in these stable transfectants (Figure 1b) . To examine the eect of avb6 suppression on in vivo tumour growth, cells expressing antisense b6 were inoculated into the¯anks of immune-de®cient athymic mice. Xenografts removed after 1 week from antisense b6 and mock transfectants (vector alone) appeared histologically similar (data not shown) but the antisense b6 expressing tumours were already smaller at that time (Figure 1e,f) . Of a total of 40 mice injected with cells expressing antisense b6 (HT29, 10 mice, and three distinct WiDr clones, 30 mice) tumours disappeared in 93% of animals and in the remaining three animals diminished to 1 mm 2 in size during the 6-week period. In contrast, of a total of 40 mice inoculated with cells expressing vector alone (mock transfectants; HT29, 10 mice, and three distinct WiDr clones, 30 mice) progressive tumour growth was observed in all animals. The tumour growth curves shown in Figure 1 (e,f) represent tumour sizes for three WiDr mock and three WiDr antisense b6 clones (10 mice each) and HT29 mock and antisense b6 transfectants (10 mice each).
We then measured the eect of down-regulating constitutive b6 expression on MAP kinase activity in both cell lines, WiDr and HT29. The percentage increase in MAP kinase activity for serum-starved cells stimulated for 30 min with serum for the cell lines WiDr (three mock and three antisense b6 clones) and HT29 (mock and antisense b6) is shown in Figure 1g . In b6-expressing cells transfected with vector alone (mock) serum stimulation increased MAP kinase (ERK1/2) activity threefold above the activity levels observed for serum-starved cells. In contrast, only a onefold increase in MAP kinase activity was observed for the antisense b6 transfectants (Figure 1g ).
The b6 integrin subunit co-immunoprecipitates with ERK
To search for b6-interacting proteins that might play a role in MAP-kinase signalling we used phage display to screen a lGT11 cDNA colon cancer cell library (CLONTECH Laboratories GmbH Heidelberg, Germany). A bait comprising the b6 cytoplasmic domain was presented as a biotinylated peptide and an interaction observed with a clone which precisely encoded the last 130 amino acids of ERK2 (Boulton et al., 1991) . We therefore probed integrin immunoprecipitates from soluble lysates derived from WiDr wild-type cells (Figure 2a ) with an anti-ERK antibody and identi®ed a protein band with a relative mobility identical to that of puri®ed phosphorylated ERK2 co-immunoprecipitating only with b6 and not with the other major integrin b subunits, b1 and b5, expressed on colon cancer cells (Agrez et al., 1996) (Figure 2b ). Three rounds of b6/b5 integrin subunit immunoprecipitation markedly depleted cells lysates of b6 and b5 integrin subunits as shown in Figure  2c . Immunodepletion of b6 but not the b5 integrin subunit substantially reduced the levels of total ERK using an anti-ERK antibody (Santa Cruz, SC1647) that recognizes both non-phosphorylated and phosphorylated ERK (Figure 2d ). This was con®rmed in reverse experiments by immunodepleting WiDr tumour cell lysates of ERK using anti-ERK antibody, SC1647, which reduced levels of b6 and its partner subunit av but not the b5 integrin subunit ( Figure  2e ). In similar experiments we were unable to coimmunoprecipitate either JNK or p38 kinases with b6 (data not shown).
The increase in cytosolic MAP kinase activity upon growth-factor stimulation is all accounted for by b6-bound ERK To determine the amount of ERK activity associated with b6 following activation of the MAP kinase pathway we compared ERK activity in non-b6 immunodepleted lysates with that in b6-immunodepleted lysates derived from cells before and after serum stimulation. In HT29 cells b6 could be completely immunodepleted from the soluble cell lysate after ®ve rounds of sequential b6 immunoprecipitation ( Figure  3a ) resulting in the loss of all serum-induced MAP kinase activity (Figure 3b ). Growth factors act through receptor tyrosine kinases, which in turn activate MAP kinases to modulate cell growth (Davis, 1993) . The . Analyses with anti-integrin antibodies against b1, b3, b5 and b6 subunits were performed as previously described (Niu et al., 2001) . White and black histograms represent analyses in the absence and presence of primary antibodies. . Anti-beta integrin antibody concentrations against individual b subunits were optimised to permit capture of approximately equivalent amounts of speci®c target protein. av which binds the b1, b5 and b6 subunits in these cells (Agrez et al., 1996) was not equilibrated in this manner to ensure sucient recovery of beta subunit-associated ERK. Molecular weight ( Puri®ed ERK is shown in the left hand lane. (e) Six rounds of sequential immunodepletion of ERK1/2 from the lysates of surface biotinylated WiDr wild-type cells using anti-ERK mAb SC1647 (that recognizes both phosphorylated and non-phosphorylated ERK1/2) or control IgG followed by immunoprecipitation of b5 and b6 integrin subunits with mAbs P1F6 and R6G9, respectively, and immunoblotting with anti-biotin antibody. Results shown in (a ± e) are representative of at least three separate experiments biological activity of EGF is mediated by the intrinsic tyrosine kinase activity of the EGF receptor (EGFR). Speci®c tyrphostins, which inhibit EGFR-dependent tyrosine kinase activity, have been shown to block growth of colorectal cancer cells in vitro (Partik et al., 1999) . Stimulation of serum-starved HT29 cells with EGF markedly enhanced the in vitro MAP kinase phosphorylation of a GST-Elk-1 fusion protein and this could be abrogated by either prior exposure of the cells to tyrphostin AG1478 or by totally immunodepleting b6 from the cell lysates ( Figure 3c ,d, respectively). These results demonstrate that in b6-expressing cells, the rise in cytosolic MAP kinase activity above basal levels upon either serum or EGF stimulation is completely accounted for by b6-bound ERK.
The b6 cytoplasmic domain binds directly to ERK
To identify the precise site of interaction on b6, a series of 20-mer peptide fragments corresponding to overlapping regions of the b6 cytoplasmic domain (amino acids 737 ± 788) were tested for their ability to bind ERK2 in a direct enzyme-linked immunosorbent assay (ELISA). Binding of the full-length b6 cytoplasmic domain to ERK2 increased in a dosedependent manner and the binding motif on b6 primarily responsible for this event resided in a 20-mer peptide designated Fragment 2 (Figure 4a) . A b6 peptide designated Fragment 5 which lacked the Cterminal ®ve amino acids from the active Fragment 2 (Figure 4a ) was equally eective in binding to ERK2 as shown in a competition assay (Figure 4b ). However, substitution of the charged arginine/lysine residues of Fragment 5 with alanine resulted in complete loss of binding to ERK2 (Figure 4c ). These results demonstrate a direct interaction between b6 and ERK2.
Deletion of the ERK2 binding site on the b6 cytoplasmic domain inhibits tumour growth
Transfection of wild-type b6 into colon cancer cells lacking avb6 has been shown to enhance tumour growth in vitro and in vivo . We therefore investigated the ability of a b6 cytoplasmic domain mutant which lacks the sequence 746 EAERSKAKWQTGTNPLYRG
764
(the ERK2 binding sequence is underlined) to bind to ERK and induce tumour formation. Surface expression of mutant and wild-type b6 subunit were similar as shown by FACScan analysis (Figure 5a ) and b1-independent adhesion of the deletion mutant to ®bronectin was minimally aected (520% reduction compared with wild-type b6; data not shown). Cell lysates containing equal protein loads were prepared from transfected SW480 cells expressing either wildtype b6, the deletion mutant or no b6 (mock transfectants) and immunoprecipitated with either mAb R6G9 (anti-b6) or isotype matched control antibody as shown in Figure 5b . Western blotting of these b6 immunoprecipitants with mAb E10 (anti-ERK recognizing phosphorylated ERK1/2) revealed no b6-bound ERK for either mock transfectants or the deletion variant compared with the wild-type receptor (Figure 5c ). Inoculation for 10 6 tumour cells into thē anks of athymic mice resulted in tumours which were 2 ± 3-fold larger for cells expressing wild-type b6 than for cells expressing either no b6 or the deletion mutant lacking the binding motif for ERK2 (Figure 5d ). Basal ERK activity in the absence of serum is less for the b6 deletion mutant than for mock transfectants (data not shown) possibly accounting for the observation that the b6 deletion mutant forms smaller tumours than non-b6 expressing cells.
The b5 integrin subunit binds ERK in cancer cells that either lack b6 or express b6 lacking the binding site for ERK2
Recently published data have shown that activated ERK translocates to the plasma membrane upon integrin ligation in non-b6-expressing cells (Fincham et al., 2000) . The SW480 cell line expresses abundant avb5 but only minimal levels of avb3 and lacks avb1 and avb6 (Agrez et al., 1996) . SW480 cells provide a model, therefore, with which to test whether the b5 integrin subunit can co-immunoprecipitate with ERK either in the absence of constitutive b6 expression or in the presence of b6 that lacks the binding site for ERK2. Cell lysates containing equal protein loads were prepared from SW480 wild-type cells and SW480 cells transfected with either vector alone (mock transfectants), wild-type b6 or the b6 deletion mutant (lacking the binding site for ERK2). The lysates were immunoprecipitated with mAbs R6G9 (anti-b6), P1F6 (anti-b5) or murine IgG (mIgG). Western blotting of the immunoprecipitates with mAb E10 recognizing phosphorylated ERK1/2 revealed no b5-bound ERK in the SW480 b6 transfectants expressing wild-type b6 in contrast to b5-associated ERK observed for the cell lines which either lack b6 or express the deletion mutant lacking the ERK2 binding sequence (Figure 6a,b) . To determine whether b5 can bind ERK2 in vitro we tested the ability of a 15-mer peptide fragment derived from the b5 cytoplasmic domain corresponding to the ERK binding domain on b6, for its ability to bind ERK2 in an ELISA assay. Dose-dependent binding of the b5 fragment ( 761 RSRARYEMASNPLYR 775 ) to ERK2 was observed as shown in Figure 6c although less avidly than the 15-mer b6 peptide. In contrast, a synthetic peptide derived from the cytoplasmic domain of the b1 subunit ( 765 KFEKEKMNAKWDTGENPIYK 784 ) which corresponds to the ERK binding domain on b6 failed to bind ERK2 (Figure 6c ).
Discussion
It is now becoming clear that MAP kinases are translocated to various cellular compartments to facilitate processes such as cell spreading, migration and proliferation and the proportion of activated ERK which is found to be nuclear-associated varies with the cell type as well as the anti-ERK antibody used (Reszka et al., 1995; Wolf et al., 2001) . For example, in non-b6-expressing rat embryo ®broblasts active ERK has been shown to be targetted to newly formed focal adhesions upon integrin engagement (Fincham et al., 2000) . MAP kinases also play a role in microtubule dynamics in various cell types and Reszka et al. (1995) have shown that half of all cellular MAP kinase activity generated by mitogenic stimulation is microtubule-associated indicating that a signi®cant proportion of MAP kinase activity is directed at substrates outside the nucleus. Our study did not permit us to estimate the proportion of total ERK (nuclear plus cytosolic) that is represented by b6-bound ERK. Importantly, epitopes targetted by speci®c anti-MAP kinase antibodies have been shown to be masked by MAP kinase-microtubule interactions possibly accounting for reported dierences in active ERK translocation to the nucleus upon growth factor stimulation (Reszka et al., 1995) . Despite the possibility of masked ERK epitopes, removal of b6 from soluble cell lysates by b6 immunodepletion resulted in the near-complete disappearance of cytosolic ERK demonstrating the speci®city of the b6-ERK interaction and suggesting that b6 binds both active and inactive ERK.
The physical interaction between an integrin involved in tumorigenesis and ERK2 de®nes a novel paradigm of integrin-mediated signalling in cancer. We have shown that suppression of either wild-type b6 expression or expression of b6 de®cient in the binding domain for ERK2 dramatically inhibits colon cancer cell growth. Upon either serum or EGF stimulation, all activated ERK within the cytoplasm is bound to the b6 integrin subunit as shown by a MAP kinase activity assay that measures phosphorylation of the ERK substrate, Elk-1. Taken together these results demonstrate that tumour growth is dependent upon direct integrin-ERK2 binding. In this model, we propose that b6 serves to direct growth factor-activated ERK to downstream cytoplasmic targets involved in regulating cell growth and/or cytoskeletal reorganization. Activation of ERK by serum-derived growth factors is greatly ampli®ed in cancer cells expressing avb6. Whether non-phosphorylated ERK, when bound to b6, is more eciently phosphorylated at that location because of conformational changes at the phosphorylation lip of ERK remains unknown. It is also possible that activated ERK, when bound to b6, is protected from deactivation by cellular phosphatases. The 15-mer ERK-binding motif identi®ed on the b6 cytoplasmic domain has considerable homology with the distinguishing characteristics of the MAP kinase docking domains of several MAP kinase binding molecules (Sharrocks et al., 2000) including a number of positively charged amino acid residues clustered at the amino terminus. Alanine substitution of all charged residues in the b6 15-mer ERK binding motif resulted in complete loss of binding of the b6 peptide to ERK2. Charge alone, however, is not the absolute determinant of the integrin-MAP kinase interaction as indicated by the inability of b5 in b6 expressing cells to bind ERK2. The b5 peptide fragment also shown to bind ERK2 in the ELISA assay, albeit less eectively than b6, shares (1 mM) to synthetic peptides comprising either the 15-mer ERK binding motif on b6 or peptide sequences derived from the b5 and b1 cytoplasmic domains that correspond to the b6-ERK binding site 50% homology with the b6-ERK2 binding sequence and contains a cluster of similarly distributed basic amino acid residues at the amino terminus of the domain. Importantly, in cells that either lack constitutive b6 expression or express b6 lacking the ERK2 binding domain, ERK appears associated with the b5 integrin subunit. The signi®cance of the b5-ERK binding event in the absence of b6 expression remains to be determined, but does raise the possibility that a hierarchy of integrin-ERK2 interactions exists within cancer cells with preferential binding of the kinase to the growth-promoting b6 subunit when it is expressed.
The inhibition of in vivo tumour growth consequent upon either down-regulation of b6 expression or loss of the ERK binding domain on b6 may be due to a combination of factors. For example, we have previously reported a direct positive correlation between levels of b6 expression in colon cancer cells and secretion of matrix metalloproteinase-9 (MMP-9) (Agrez et al., 1999) . Furthermore, exposure of tumour cells to a speci®c MMP inhibitor abolishes b6-mediated tumour cell proliferation and colony spreading within a collagen matrix (Agrez et al., 1999) . Maximal expression of both MMPs and b6 has been observed at the invading margin of tumour cell islands in colon cancer (Hewitt et al., 1995; Agrez et al., 1996) and MMP-9 production has been shown to be directly dependent on the activation of ERK signalling in epithelial cells (Zeigler et al., 1999; McCawley et al., 1999; Johansson et al., 2000) . Downstream targets for ERKs include not only nuclear transcription factors such as c-myc but also cytosolic targets (e.g., 90 kDa ribosomal S6 protein kinase family; RSKs) involved in regulating cell growth (Kerkho et al., 1998; Bonni et al., 1999) . In non-epithelial cells RSKs have been shown to catalyse phosphorylation of the pro-apoptotic protein BAD (Bonni et al., 1999) . Another critical target of RSKs is the transcription factor CREB (cyclic AMP response element-binding protein) (Xing et al., 1996) . Hence, the MAP kinase signalling pathway can promote cell survival by modulating the cell death machinery through inhibition of the pro-apoptotic protein BAD and by inducing expression of pro-survival genes in a CREB-dependent manner (Bonni et al., 1999) . Whether or not the b6-ERK interaction in colon cancer cells mediates similar downstream events is currently under investigation.
A highly potent inhibitor of MAP kinase activation has been shown to inhibit human colon cancer growth in immuno-de®cient mice (Sebolt-Leopold et al., 1999) . However, tumour cell speci®city remains a potential problem with this approach because MAP kinases are involved in a wide range of normal cellular processes (Duesbery et al., 1999) . Given that de novo b6 expression occurs in tumorigenesis, targetting either b6 or its MAP kinase interaction may oer greater therapeutic speci®city in cancer treatment. The interaction and reagents described herein may also provide a suitable method for high-throughput screening of inhibitors of this binding event.
Materials and methods

Antibodies and reagents
The monoclonal antibody (mAb) L230 (IgG 1 ) against the integrin av subunit was prepared from hybridoma cells obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). Monoclonal antibodies E7P6 (IgG 1 ) and R6G9 (IgG 2a ) against the integrin b6 subunit and PIF6 (IgG 1 ) against the integrin b5 subunit, have been described previously . Monoclonal antibodies QE2E5 (IgG 2a ) and mAb 13 (IgG 2a ) against the integrin b1 subunit were obtained from G Russ (Queen Elizabeth Hospital, Adelaide, Australia) and Becton Dickinson (San Jose, CA, USA), respectively. Phycoerythrinconjugated goat anti-mouse IgG was obtained from Chemicon (Temecula, CA, USA) and rabbit anti-mouse immunoglobulin from DAKO (Denmark). Protein A-Sepharose CL-4B was obtained from Amersham Pharmacia Biotech (Uppsala, Sweden). Reagents for SDS-polyacrylamide gel electrophoresis (SDS ± PAGE) and molecular weight markers were purchased from Bio-Rad Laboratories (Hercules, CA, USA). Mouse immunoglobulins, epidermal growth factor (EGF) and tyrphostin AG1478 were purchased from SigmaAldrich (St Louis, MO, USA).
Cell lines and culture conditions
The human colon cancer cell lines, WiDr, HT29 and SW480 were obtained from the ATCC and maintained as monolayers in standard medium comprising Dulbecco's Modi®ed Eagle's Medium (DMEM; 4.5 gm/litre of glucose) containing 10% heat-inactivated foetal calf serum (FCS) and supplemented with 20 mM HEPES, 100 IU/ml penicillin and 100 mg/ml streptomycin. SW480 colon cancer cells, which lack constitutive avb6 expression, were stably transfected with pcDNA1neo constructs containing either the b6 gene construct or the expression plasmid only as previously described . WiDr and HT29 cells, which express endogenous b6, were stably transfected with b6 in antisense orientation. b6 cDNA was excised from the vector pcDNA1neob6 and re-ligated into the vector pEF.PGK.puro (a gift from D Huang, The Walter and Eliza Hall Institute, Melbourne, Australia), which uses the promoter from the human polypeptide chain elongation factor-1a. Orientation of b6 in pEFpuro was con®rmed by sequence analysis and stable transfectants were selected continuously in puromycin (WiDr, 1 mg/ml; HT29, 2.5 mg/ml). Mock transfectants were transfected with vector alone. Three mock and three antisense b6 transfected clones were established from the WiDr cell line. The b6 cytoplasmic domain deletion mutant transfected into the SW480 cell line has been previously reported and was a gift from D Sheppard (Lung Biology Centre, University of California, San Francisco, CA, USA).
FACScan and b6 transcript analysis
FACScan analyses with anti-integrin antibodies were performed as previously described (Niu et al., 2001) . For b6 Northern analyses, a b6 probe was prepared by restriction endonuclease digest of full-length b6 from pcDNA1neob6 followed by restriction digest of the b6 insert with SSP1. The larger of the two fragments obtained (1700 bp) was labelled with a 32 P-dCTP using a Prime It II Random Primer Labelling kit (Stratagene, La Jolla, CA, USA). A total cellular RNA of 2 ± 3 mg was separated on a 1% agarose gel containing formaldehyde and transferred to Hybond N + Direct integrin-ERK binding in cancer cells N Ahmed et al membrane. Following hybridization with the b6 probe and autoradiographic development, membranes were stripped and rehybridized with a radiolabelled DNA probe for GAPDH.
Tumorigenicity assay
The ability of human colon cancer cells to form tumours in immuno-de®cient athymic nude mice (Animal Resource Centre, Perth, Western Australia) was assessed by measuring length and breadth of tumours during a 6-week period following subcutaneous inoculation of 10 6 viable tumour cells suspended in 100 ml of standard complete culture medium (DMEM). Formalin-®xed sections of tumours were excised after 1 week and stained with haematoxylin-eosin.
Western blotting and immunoprecipitation
Cells were cultured as adherent monolayers in plastic tissue culture¯asks in complete DMEM before being serum starved for 24 h prior to addition of either FCS (10% for 30 min) or EGF (50 ng/ml for 10 min). Cells were then recovered using Trypsin/EDTA, the Trypsin neutralized with complete DMEM and cell pellets washed with ice cold PBS before lysis in Buer A (100 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM CaCl 2 , 1% Triton X-100, 0.1% SDS, 0.1% NP-40, 1 mM vanadate, 1 mg/ml pepstatin, 1 mM PMSF, 5 mg/ml aprotinin and 1 mg/ml of leupeptin). Lysates were stood at 48C for 30 min and clari®ed at 10 000 g for 10 min at 48C to remove detergent-insoluble material. Soluble lysate was recovered and used in all subsequent analyses. Integrin immunoprecipitations either before or after ERK immunodepletion were performed following biotinylation of cell surface proteins with biotin-CNHS-ester in Buer B (10 mM sodium borate, 150 mM NaCl, pH 8.8) to determine expression levels of integrin subunits. A portion of immunoprecipitated biotinylated integrin was separately electrophorezed for immunoblotting with anti-ERK antibody. All proteins were resolved by SDS ± PAGE under non-reducing conditions. Separated proteins were electrophoretically transferred to nitrocellulose membrane and immunoblotted with either a monoclonal antibody which recognizes phosphorylated ERK1/2 (mAb E10, New England BioLabs, Beverly, MA, USA), both phosphorylated and non-phosphorylated ERK1/ 2 (mAb SC1647; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-biotin mAb (Sigma). Where comparative immunoprecipitations were carried out protein concentrations of detergent soluble cell lysates were determined (BCA Protein Assay Kit, Pierce, Rockford, IL, USA) and protein concentrations made equivalent (1 mg/ml of protein) with complete lysis buer before immunoprecipitation. All lysates were then pre-cleared with rabbit-anti-mouse Ig coupled to Sepharose CL-4B beads. Anti-beta integrin antibody concentrations against individual b subunits were optimized to permit capture of approximately equivalent amounts of speci®c target protein. In ERK immunodepletion experiments six rounds of ERK immunodepletions were performed using mAb SC1647 which recognizes both phosphorylated and non-phosphorylated ERK1/2. Preliminary experiments showed that six sequential immunoprecipitations completely removed all soluble ERK from the lysate (data not shown).
MAP kinase assay
Cultures of WiDr and HT29 mock and antisense b6 transfectants were established by seeding 1610 6 cells/5 ml of complete culture medium in 25 cm 2 tissue culture¯asks. Cells were incubated at 378C in humidi®ed CO 2 for 24 h before serum starvation in serum-free medium for the next 16 h. FCS was then added to a ®nal concentration of 10% for 30 min and the cells then washed twice with ice cold PBS before resuspension in extraction buer (10 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 2 mM DTT, 1 mM orthovanadate, 1 mM PMSF, 4 mg/ml aprotonin, 2 mg/ml leupeptin and 1 mg/ml pepstatin, pH 7.4). The cell suspension was sonicated on ice at a setting of 7 using a Soniprep 150 watt ultrasonic disintegrator using three 30 s pulses with an interval of 30 s between each pulse. Cellular debris was removed by centrifugation at 900 g for 10 min at 48C. A MAP kinase assay was performed on sonicates from equal cell numbers using a MAP kinase assay system (Amersham Pharmacia Biotech). The ability of cell-derived sonicates to transfer phosphate from [g 32 P]ATP to a synthetic peptide containing a p42/p44 MAP kinase speci®c phosphorylation site was quantitated as described in the manufacturer's instructions. Brie¯y, 32 P-labelled peptides were spotted onto PE1-cellulose paper, non-peptide bound radioactivity removed by washing with 75 mM phosphoric acid and bound 32 P-labelled peptides measured by liquid scintillation counting. Protein estimation was performed on each cell sonicate used and enzyme activity calculated as described in the manufacturer's instructions.
In vitro MAP kinase activity assays were also performed using a non-radioactive assay kit (Cell Signaling Technology, Beverly, MA, USA) which measures phosphorylation of the ERK1/2 substrate Elk-1 presented as a fusion protein comprising the Elk-1 codons 307-428 coupled to GST. In this assay ERK kinase was ®rst immunoprecipitated from complete or integrin-immunodepleted soluble cell lysates and relative enzyme activity determined by the in vitro phosphorylation of GST-Elk-1.
Enzyme-linked immunosorbent assay (ELISA)
Biotin-coupled synthetic peptide fragments corresponding to regions of the b6 cytoplasmic domain (amino acids 737 ± 788) were purchased from Auspep (Melbourne, Australia). A serine residue was substituted for the C-terminal cysteine in b6 to avoid dimerization during synthesis of the 20 mer b6 peptide fragments but not the 52 mer full-length b6 cytoplasmic domain. ERK2 was expressed as a GST-fusion protein in the pGEX 4T vector (from C Marshall, Institute of Cancer Research, London, UK). The fusion protein (GST-ERK2) was cleaved using thrombin to cleave GST and GST (both free and remnant uncleaved fusion protein) removed by clearance with glutathione-agarose. ERK2 purity was routinely assessed by silver stained SDS ± PAGE. Biotinylated peptides were attached onto streptavidin-coated 96-well polystyrene plates obtained from Pierce (Rockford, IL, USA, Cat. No. 15125) and ELISAs performed according to the manufacturer's instructions. The eciency of binding of ERK2 to immobilized peptides was determined using anti-ERK antibody (SC1647, Santa Cruz, CA, USA) followed by an anti-species alkaline phosphatase conjugated antibody and colourimetric development. In competition assays, ERK2 was coated directly onto plastic ELISA plates (Nunc) and the binding of a biotinylated peptide determined in the absence/ presence of the competing non-biotinylated peptide using anti-biotin antibody (Sigma-Aldrich). 
